These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15919648)

  • 21. Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steel-tantalum-stainless steel phosphorylcholine-coated stent: the TriMaxx trial.
    Abizaid A; Popma JJ; Tanajura LF; Hattori K; Solberg B; Larracas C; Feres F; Costa Jde R; Schwartz LB
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):914-9. PubMed ID: 18044791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus.
    Ali RM; Degenhardt R; Zambahari R; Tresukosol D; Ahmad WA; Kamar Hb; Kui-Hian S; Ong TK; bin Ismail O; bin Elis S; Udychalerm W; Ackermann H; Boxberger M; Unverdorben M
    EuroIntervention; 2011 May; 7 Suppl K():K83-92. PubMed ID: 22027736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents.
    Wang TY; Hasselblad V; Peterson JL; Wijns W; Parhizgar A; Kereiakes DJ; Krucoff MW
    Am Heart J; 2007 May; 153(5):743-8. PubMed ID: 17452147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model.
    New G; Moses JW; Roubin GS; Leon MB; Colombo A; Iyer SS; Tio FO; Mehran R; Kipshidze N
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):266-71. PubMed ID: 12357534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents.
    Serruys PW; Daemen J
    Circulation; 2007 Mar; 115(11):1433-9; discussion 1439. PubMed ID: 17344323
    [No Abstract]   [Full Text] [Related]  

  • 28. Promises of biodegradable stents.
    Hehrlein C
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):739. PubMed ID: 17390303
    [No Abstract]   [Full Text] [Related]  

  • 29. [Restenosis in a cobalt-chromium stent 36 months after implantation into the right coronary artery].
    Koziński M; Rychter M; Gadzińska A; Sukiennik A; Kubica J
    Kardiol Pol; 2008 Sep; 66(9):1002-6; discussion 1007. PubMed ID: 18924034
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug eluting stents for everyone and everything?
    Laham RJ
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):512-3. PubMed ID: 16270362
    [No Abstract]   [Full Text] [Related]  

  • 31. Direct comparison of the short-term clinical performance of Z Guidant and Taxus stents.
    Guildford A; Colombo P; Bruschi G; Bonacina E; Klugmann S; Santin M
    Int J Cardiol; 2010 Dec; 145(3):e83-5. PubMed ID: 19178961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease.
    Kalnins U; Erglis A; Dinne I; Kumsars I; Jegere S
    Med Sci Monit; 2002 Feb; 8(2):PI16-20. PubMed ID: 11859292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial-cell-binding aptamer for coating of intracoronary stents.
    Strahm Y; Flueckiger A; Billinger M; Meier P; Mettler D; Weisser S; Schaffner T; Hess O
    J Invasive Cardiol; 2010 Oct; 22(10):481-7. PubMed ID: 20944188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent.
    Zheng H; Barragan P; Corcos T; Siméoni JB; Favereau X; Roquebert PO; Guérin Y; Sainsous J
    J Invasive Cardiol; 1999 Oct; 11(10):608-14. PubMed ID: 10745442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease.
    Airoldi F; Di Mario C; Ribichini F; Presbitero P; Sganzerla P; Ferrero V; Vassanelli C; Briguori C; Carlino M; Montorfano M; Biondi-Zoccai GG; Chieffo A; Ferrari A; Colombo A
    Am J Cardiol; 2005 Sep; 96(5):664-7. PubMed ID: 16125491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
    Fajadet J; Wijns W; Laarman GJ; Kuck KH; Ormiston J; Münzel T; Popma JJ; Fitzgerald PJ; Bonan R; Kuntz RE;
    Minerva Cardioangiol; 2007 Feb; 55(1):1-18. PubMed ID: 17287679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
    Schofer J; Schlüter M; Gershlick AH; Wijns W; Garcia E; Schampaert E; Breithardt G;
    Lancet; 2003 Oct; 362(9390):1093-9. PubMed ID: 14550694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zotarolimus (ABT-578) eluting stents.
    Burke SE; Kuntz RE; Schwartz LB
    Adv Drug Deliv Rev; 2006 Jun; 58(3):437-46. PubMed ID: 16581153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current status of stent placement in small coronary arteries < 3.0 mm in diameter.
    Lau KW; Hung JS; Sigwart U
    J Invasive Cardiol; 2004 Aug; 16(8):411-6. PubMed ID: 15282416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary stenting challenges: technique, design and pharmacology.
    Linnemeier TJ
    J Invasive Cardiol; 1999 Jan; 11(1):43-6; discussion 46. PubMed ID: 10745437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.